United Therapeutics (UTHR) Total Current Liabilities (2009 - 2026)

United Therapeutics has disclosed Total Current Liabilities across 18 years of filings, most recently posting $607.8 million for Q2 2026.

• In Q2 2026, Total Current Liabilities rose 15.31% year-over-year to $607.8 million; the TTM figure through Jun 2026 stood at $607.8 million (up 15.31% YoY), while the FY2025 annual figure was $560.6 million, down 24.05% from the prior year.
• Total Current Liabilities came in at $607.8 million for Q2 2026 at United Therapeutics, up from $599.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $873.4 million in Q3 2024 to a low of $292.6 million in Q1 2022.
• Average Total Current Liabilities over 5 years is $577.4 million, with a median of $579.8 million recorded in 2025.
• Year-over-year, Total Current Liabilities jumped 165.13% in 2024 and tumbled 37.45% in 2025.
• Over 5 years, Total Current Liabilities stood at $343.2 million in 2022, then soared by 134.38% to $804.4 million in 2023, then fell by 8.24% to $738.1 million in 2024, then slipped by 24.05% to $560.6 million in 2025, then climbed by 8.42% to $607.8 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $607.8 million in Q2 2026, $599.1 million in Q1 2026, and $560.6 million in Q4 2025.